The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC).
Edward Samuel James
No relevant relationships to disclose
Xiaopan Yao
No relevant relationships to disclose
Xiangyu Cong
No relevant relationships to disclose
Jia Li
No relevant relationships to disclose
Carol Hahn
No relevant relationships to disclose
Kristin Kaley
No relevant relationships to disclose
Jeremy S. Kortmansky
No relevant relationships to disclose
Neal A. Fischbach
No relevant relationships to disclose
Bryan William Chang
No relevant relationships to disclose
Ronald R Salem
No relevant relationships to disclose
Charles Cha
No relevant relationships to disclose
Stacey Stein
No relevant relationships to disclose
Howard S. Hochster
No relevant relationships to disclose
Jill Lacy
No relevant relationships to disclose